Vivek Subbiah: F.D.A. Grants Early Access to Promising Drug for Pancreatic Cancer
oncodaily - Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn: “Wow! It’s Big news on Friday. F.D.A. Grants Early Access to Promising Drug for […]
AI Summary: The FDA has authorized early access to a promising experimental therapy for pancreatic cancer, opening an expanded‑access pathway so eligible patients can receive the drug before full approval. Regulators based the decision on encouraging early clinical signals of activity and manageable safety data, aiming to offer options for a disease with few effective treatments—because pancreatic cancer isn’t known for its patience.
- Daraxonrasib expanded access: FDA opens early pathway (6)
- Research advances: diagnostics and targeted therapies for pancreatic cancer (5)
- All Other Stories
Daraxonrasib expanded access: FDA opens early pathway
Research advances: diagnostics and targeted therapies for pancreatic cancer
All Other Stories
Related Stories
Daraxonrasib’s ASCO moment sparks rapid clinical uptake for pancreatic cancer / 13 days
FDA greenlights datopotamab deruxtecan for metastatic TNBC / 14 days
FDA approves belzutifan (Welireg) plus pembrolizumab for adjuvant RCC / 21 days
FDA clears first all-oral regimen for certain newly diagnosed AML patients / 5 wks
Daraxonrasib improves survival versus chemotherapy in metastatic pancreatic cancer / 5 wks
VOLGA Phase III shows survival benefit for bladder cancer neoadjuvant combo / 1 month
New drug doubles one-year survival in metastatic pancreatic cancer / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Trump Administration, Diagnostics, Vaccine Safety, Oncology and look for the RSS link.
StackHealth Time Machine